

May 4, 2023

NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(b)

Subject: New prescription drug report

To: The Office of the Attorney General of Vermont

Ingenus Pharmaceuticals, LLC hereby submits to the Attorney General of Vermont of the following new prescription drug reporting requirements pursuant to 18 V.S.A. § 4637(b):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	Wholesale Acquisition Cost as of the date of Commercial Availability
Gefitinib Tablets 250mg, 30 count	50742036630	05/03/2023	\$3995.00

Marketing Plan Description:

This is a generic product that is not marketed.

Estimated Number of Patients:

Ingenus does not track estimated number of patients.

Breakthrough Therapy/Priority Review/Acquisition Date:

Gefitinib was not granted breakthrough therapy designation or priority review by the FDA, and it was not an acquired product.

Ingenus believes that this report contains all the required report elements for a new prescription drug report. Please let us know if any additional information is required.

Sincerely,



Sandy Fischer
AVP Compliance and Commercial Operations